Genprex, Inc. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Genprex, Inc. stock issued during period, value, issued for services for the quarter ending 2026-06-30 was $7.90K, a 97.84% decline year-over-year.
- Genprex, Inc. stock issued during period, value, issued for services for the quarter ending 2026-03-31 was $8.95K, a 98.43% increase year-over-year.
- Genprex, Inc. stock issued during period, value, issued for services for the quarter ending 2025-09-30 was $1.33K, a 86.17% decline year-over-year.
- Genprex, Inc. stock issued during period, value, issued for services for the quarter ending 2025-06-30 was $366.71K, a 2369.46% increase year-over-year.
- Genprex, Inc. stock issued during period, value, issued for services for fiscal 2025 was $7.95K, a 96.16% decline from fiscal 2024.
- Genprex, Inc. stock issued during period, value, issued for services for fiscal 2024 was $206.99K, a 988.82% increase from fiscal 2023.
- Genprex, Inc. stock issued during period, value, issued for services for fiscal 2023 was $19.01K, a 88.35% decline from fiscal 2022.
- Genprex, Inc. stock issued during period, value, issued for services for fiscal 2022 was $163.23K, a 4.61% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2026-06-30 | $7.90K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $8.95K 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $7.95K 10-K · filed 2026-03-30 | |
| 2025-09-30 | $1.33K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $366.71K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $4.51K 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $206.99K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $9.65K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $14.85K 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $180.72K 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $19.01K 10-K · filed 2025-04-01 | |
| 2023-09-30 | $4.79K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $4.40K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $21.89K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $163.23K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $6.90K 10-Q · filed 2023-11-14 | $139.87K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $17.97K 10-Q · filed 2023-11-14 | $149.77K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-03-31 | $17.50K 10-Q · filed 2023-11-14 | $152.90K derived: sum of 4 quarters · filed 2023-11-14 |
| 2021-12-31 | $97.50K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $156.04K 10-K · filed 2023-03-31 |
| 2021-09-30 | $16.80K 10-Q · filed 2022-11-14 | $185.30K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $21.10K 10-Q · filed 2022-11-14 | $183.85K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-03-31 | $20.65K 10-Q · filed 2022-11-14 | $173.75K derived: sum of 4 quarters · filed 2022-11-14 |
| 2020-12-31 | $126.75K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $154.65K 10-K · filed 2022-03-30 |
| 2020-09-30 | $15.35K 10-Q · filed 2021-11-15 | $105.06K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $11.00K 10-Q · filed 2021-11-15 | $130.64K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-03-31 | $1.55K 10-Q · filed 2021-11-15 | $278.74K derived: sum of 4 quarters · filed 2021-11-15 |
| 2019-12-31 | $77.16K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | $469.59K 10-K · filed 2021-03-26 |
| 2019-09-30 | $40.94K 10-Q · filed 2019-11-14 | $769.09K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $159.10K 10-Q · filed 2020-11-12 | $561.04K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-03-31 | $192.40K 10-Q · filed 2020-11-12 | $578.59K derived: sum of 4 quarters · filed 2020-11-12 |
| 2018-12-31 | $376.65K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $553.30K 10-K · filed 2020-03-30 |
| 2018-09-30 | -$167.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $362.85K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $176.65K 10-Q · filed 2019-11-14 | |
| 2018-03-31 | $176.65K 10-Q · filed 2019-11-14 | |
| 2017-12-31 | $176.65K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $1.10M 10-K · filed 2019-04-01 |
| 2016-12-31 | $419.45K 10-K · filed 2018-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |